Department of Pediatrics
Administration, Oral; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Transmission, Vertical; Drug Therapy, Combination; Female; HIV Infections; *HIV-1; Humans; Infant; Male; Nevirapine; Pyridines; RNA, Viral; Viral Load; Zidovudine
Life Sciences | Medicine and Health Sciences
BACKGROUND: In infants and children with maternally acquired human immunodeficiency virus type 1 (HIV-1) infection, treatment with a single antiretroviral agent has limited efficacy. We evaluated the safety and efficacy of a three-drug regimen in a small group of maternally infected infants. METHODS: Zidovudine, didanosine, and nevirapine were administered in combination orally to eight infants 2 to 16 months of age. The efficacy of antiretroviral treatment was evaluated by serial measurements of plasma HIV-1 RNA, quantitative plasma cultures, and quantitative cultures of peripheral-blood mononuclear cells. RESULTS: The three-drug regimen was well tolerated, without clinically important adverse events. Within four weeks, there were reductions in plasma levels of HIV-1 RNA of at least 96 percent (1.5 log) in seven of the eight study patients. Over the 6-month study period, replication of HIV-1 was controlled in two infants who began therapy at 2 1/2 months of age. Plasma RNA levels were reduced by 0.5 to 1.5 log in five of the other six infants. CONCLUSIONS: Although further observations are needed, it appears that in infants with maternally acquired HIV-1 infection, combined treatment with zidovudine, didanosine, and nevirapine is well tolerated and has sustained efficacy against HIV-1.
N Engl J Med. 1997 May 8;336(19):1343-9.
The New England journal of medicine
Luzuriaga K, Bryson YJ, Krogstad PA, Robinson JE, Stechenberg B, Lamson M, Cort S, Sullivan JL. (1997). Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. Open Access Publications by UMMS Authors. Retrieved from https://escholarship.umassmed.edu/oapubs/1686